← Eichor
Condition: Neuroblastoma In Children Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Neuroblastoma In Children

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
EARLY_Phase 1 · 12 location(s) · C17 Council · NCT06942039Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 · 162 location(s) · Children's Oncology Group · NCT03126916N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06528496Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Milton S. Hershey Medical Center · NCT06541262PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Theodore Laetsch · NCT06721689Biomarkers of Resiliency In Childhood Cancer Surgery
Phase N/A · 1 location(s) · Mayo Clinic · NCT06674811Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
Phase N/A · 1 location(s) · University Hospital, Clermont-Ferrand · NCT07141862GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Phase 1 · 1 location(s) · Stanford University · NCT07087002Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Phase 1 · 1 location(s) · Marzieh Ebrahimi · NCT06674265APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Phase 1 · 3 location(s) · Ascentage Pharma Group Inc. · NCT05701306DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Phase 2 · 5 location(s) · Jakob Stenman · NCT04903899Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07502287Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
NA · 1 location(s) · Beijing Children's Hospital · NCT06818916Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07318831Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/
Phase 1 · 1 location(s) · Emory University · NCT05400603Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
NA · 6 location(s) · Dana-Farber Cancer Institute · NCT06831552Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Phase 1 · 1 location(s) · New York Medical College · NCT04308330
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.